Prohibiting MG53 Phosphorylation Optimizes Its Therapeutic Potential in Diabetes.
Duane D. Hall,Qian Shi,Long‐Sheng Song
DOI: https://doi.org/10.1161/circresaha.122.322132
IF: 23.213
2022-01-01
Circulation Research
Abstract:HomeCirculation ResearchVol. 131, No. 12Prohibiting MG53 Phosphorylation Optimizes its Therapeutic Potential in Diabetes Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBProhibiting MG53 Phosphorylation Optimizes its Therapeutic Potential in Diabetes Duane D. Hall, Qian Shi and Long-Sheng Song Duane D. HallDuane D. Hall https://orcid.org/0000-0003-2228-0966 Division of Cardiovascular Medicine, Department of Internal Medicine, Abboud Cardiovascular Research Center, Carver College of Medicine, University of Iowa. , Qian ShiQian Shi https://orcid.org/0000-0003-2634-9553 Division of Cardiovascular Medicine, Department of Internal Medicine, Abboud Cardiovascular Research Center, Carver College of Medicine, University of Iowa. and Long-Sheng SongLong-Sheng Song Correspondence to: Long-Sheng Song, MD, FAHA, FISHR Department of Internal Medicine, Carver College of Medicine, University of Iowa, 285 Newton Rd, Iowa City, IA 52242, Email E-mail Address: [email protected] https://orcid.org/0000-0002-6035-8106 Division of Cardiovascular Medicine, Department of Internal Medicine, Abboud Cardiovascular Research Center, Carver College of Medicine, University of Iowa. Originally published1 Dec 2022https://doi.org/10.1161/CIRCRESAHA.122.322132Circulation Research. 2022;131:977–979This article is a commentary on the followingBlocking MG53S255 Phosphorylation Protects Diabetic Heart From Ischemic InjuryOrgan damage from diabetes drastically reduces patient quality of life and places an enormous burden on healthcare systems across the globe. The heart is particularly affected in type 2 diabetic patients with most deaths attributed to cardiovascular complications. During diabetes, heart function is impaired with compromised cellular signaling, making it more susceptible to additional insults such as myocardial infarction and ischemia/reperfusion (I/R) injury.1 Diabetes is a risk factor for ischemic heart disease as evidenced by a 2- to 4-fold increase in the incidence of myocardial infarction in patients with diabetes compared to those without diabetes. Understanding how diabetes sets the stage for increased myocardial damage has important clinical implications.Article, see p 962The heart is an insulin responsive organ.1 Cardiac insulin signaling mediates cellular homeostasis via control of protein synthesis, substrate utilization, and cell survival. In a healthy heart, insulin activates phosphoinositide-3-kinase-Akt signaling and promotes GLUT4 translocation to the cell surface to facilitate glucose transport. Under normal conditions, the heart primarily uses lipid as a fuel via aerobic metabolism. However, during ischemia, the heart shifts its energy production from aerobic metabolism to anaerobic metabolism, in which anaerobic glycolysis becomes important in the preservation of myocardial viability. The impaired ability to utilize glucose due to blunted insulin responsiveness, that is, insulin resistance, contributes to the pathology of the diabetic heart.MG53, also known as TRIM72, has been shown to regulate insulin sensitivity in skeletal and cardiac myocytes. MG53 is highly enriched in striated muscle and promotes the ubiquitination and degradation of insulin receptor (IR)α/β and insulin receptor substrate 1 (IRS1).2,3 The E3 ubiquitin ligase function of MG53 localizes to its N-terminus and within its tripartite motif consisting of RING, B-box, and coiled-coil sequences. A cystine to alanine mutation at residue 14 (C14A) in the RING domain of MG53 blocks its E3 ligase activity and prevents ubiquitination of its substrates including IR α/β and IRS1.2,3 The function of the central and C-terminal regions of MG53, on the contrary, acts to repair damaged membranes. Adult differentiated myocytes have limited regenerative capacity and therefore rely on effective membrane repair mechanisms for cell survival. Upon membrane rupture and exposure to the oxidizing extracellular environment, MG53 oligomerizes through interchain Cystine 242 disulfide bond formation and translocates to membrane rupture sites with bound vesicles to facilitate membrane repair using its PRY/SPRY domain.4 How the separate degradation versus reparative activities of MG53 contribute to its overall function has yet to be fully understood. Genetic manipulation of MG53 suggests its membrane repair function dominates under basal conditions. MG53 null mice have a progressive skeletal myopathy and exhibit diminished myocyte membrane repair after exercise.4 However, cardiomyocyte transverse-tubule membrane integrity remains intact in the absence of MG53 at baseline and over a long period of time. Under mechanic pressure overload stress, MG53 deletion leads to more severe cardiac dysfunction as a result of exacerbated T-tubule degeneration, likely due to the loss of MG53-mediated membrane repair function.5Interestingly, MG53 is not locally restrained to the damaged myocyte from where it is produced but is also effectively released into the circulation during exercise and pathological stress including myocardial infarction and I/R injury.6,7 Several studies have now demonstrated that circulating MG53 can act as an important systemic myokine for recruitment to sites of organ damage. Intravenous injection of recombinant human MG53 (rhMG53) reduces the pathological consequences from muscular dystrophy and kidney injury, among other models.8,9 In a similar fashion, transgenic expression of serum-targeted MG53 in MG53 null mice demonstrates its systemic myokine function is distinct from its intracellular role10 and can even cross the blood-brain barrier to facilitate recovery from neuronal I/R injury.11Given its ability to ubiquitinate insulin signaling molecules for their degradation, there is growing interest into whether intracellular or systemic MG53 plays a role in the pathogenesis of diabetes. MG53 deleted mice are protected against high-fat diet-induced hyperglycemia, hyperlipidemia, and insulin insensitivity.2,3 In parallel, insulin stimulation of MG53 knockout skeletal myocytes results in higher levels of total and phosho-IRS1 and phospho-Akt compared to wildtype myocytes suggesting insulin signaling is elevated in MG53 null muscle through reduced MG53-dependent ubiquitination. On the other hand, insulin triggers MG53 secretion from skeletal and cardiac tissue both in normal and diabetic animals.7,12 The consequences of circulating MG53 on diabetic outcomes apart from its intracellular role has begun to be explored but remains a matter of debate.12Mechanistic studies that differentiate between the positive actions of MG53 on membrane repair from its negative effects on insulin signaling would be expected to shed light into the function of MG53 in the context of diabetes and diabetic cardiomyopathy. Xiao and colleagues wondered if the E3 ligase function of MG53 could be manifested more clearly in diabetic animals subjected to myocardial ischemic events. Earlier this year, the Xiao group found that E3 ligase deficient knock-in mutation of MG53 (C14A) or systemic administration of rhMG53-C14A protein is more effective at protecting mice from myocardial infarction and I/R damage than wildtype (WT) MG53 controls,13 supporting the idea MG53 ligase activity is detrimental in diabetic animals upon organ damage.In this issue, Lv et al14 extended their findings into MG53 ligase function by exploring whether endogenous kinases act to shift the balance between MG53 substrate ubiquitination and membrane healing activities (Figure). By performing mass spectrometry analysis on MG53 immunoprecipitated from skeletal myocytes and heterologously expressing HEK cells, the residue Serine 255 was found to be phosphorylated in both groups and among 5 phosphosites in the muscle expressed protein. Of the candidate-phosphorylated residues, only mutation of Serine 255 to alanine (S255A), which prevents phosphorylation of the residue, blocked the ubiquitination and downregulation of IRS1 and IRβ in cultured neonatal rat ventricular myocytes and immortalized C2C12 myotube cells. Mimicking phosphorylation of Serine 255 by aspartate and glutamate substitution had no effect on IRS1 and IRβ downregulation suggesting Serine 255 is basally phosphorylated. Serine 255 appears to mediate MG53 recognition of its substrates as MG53 S255A mutants fail to interact with either IRS1 or IRα.Download figureDownload PowerPointFigure. Schematic diagram showing the dual paradoxical functions of MG53 protein (left), and how modifications of key residues transform MG53 into a single purposed therapeutic (right).Prediction analyses suggests Serine 255 is a GSK3β consensus site. Using skeletal muscle lysates, GSK3β was found to reciprocally co-immunoprecipitate with MG53. Furthermore, inhibition of GSK3 blunted MG53 phosphorylation at Serine 255 and MG53-S255A mutation blocked the ubiquitination of IRS1 in response to GSK3 overexpression. These results establish that a mechanistic feedback loop exists between insulin sensitivity, GSK3β, and MG53. Examination of cardiac tissue from several rodent and nonhuman primate models of metabolic syndrome revealed that IRS1, IRβ, and inhibitory GSK3β phosphorylation levels are decreased in parallel with increased MG53 phosphorylation at Serine 255. Furthermore, the S255A mutation does not affect the membrane repair function of MG53. Overexpression of MG53-WT and MG53-S255A constructs equally protected neonatal rat ventricular myocytes against hypoxia-induced cell death. Exogenously applied rhMG53-WT and rhMG53-S255A protein both attenuated hypoxic LDH release and cell death as well as accelerated the healing of detergent-ruptured myocyte membranes.Cumulatively, these findings suggested MG53 phosphorylation at Serine 255 is a pathologically relevant modification. To investigate the translational potential of MG53, the authors studied short- and long-term consequences from myocardial infarction and I/R in spontaneously diabetic db/db animals treated with rhMG53-WT or rhMG53-S255A. In each scenario, rhMG53-S255A was found to be more effective than rhMG53-WT at improving cardiac outcomes from ischemic and reperfusion injury.In summary, the study by Lv et al14 provides new insights into how MG53 targets protein substrates for ubiquitination. In diabetic heart, GSK3-dependent phosphorylation of MG53 at Serine 255 increases MG53 recognition, ubiquitination, and degradation of critical insulin signaling pathway proteins, contributing to insulin resistance and increased susceptibility to ischemic injury. Preventing Serine 255 phosphorylation by GSK3 potentiates the beneficial effect of MG53 in limiting the degree of cardiac damage from ischemic events in the context of metabolic disease. It will be important for future studies to determine whether other MG53 ubiquitinated substrates in addition to IRs and IRS1 contribute to end-organ damage. Also important to address is whether Serine 255 directly affects the E3 ligase activity of MG53 or only prevents MG53 from finding its substrates. Another open question is whether Serine 255 phosphorylation also contributes to self-dimerization and/or membrane fusion in addition to its effects on substrate ubiquitination.Article InformationDisclosures None.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Disclosures, see page 979.Correspondence to: Long-Sheng Song, MD, FAHA, FISHR Department of Internal Medicine, Carver College of Medicine, University of Iowa, 285 Newton Rd, Iowa City, IA 52242, Email long-sheng-song@uiowa.eduReferences1. Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac energy metabolism in heart failure.Circ Res. 2021; 128:1487–1513. doi: 10.1161/CIRCRESAHA.121.318241LinkGoogle Scholar2. Song R, Peng W, Zhang Y, Lv F, Wu HK, Guo J, Cao Y, Pi Y, Zhang X, Jin L, et al. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders.Nature. 2013; 494:375–379. doi: 10.1038/nature11834CrossrefMedlineGoogle Scholar3. Yi JS, Park JS, Ham YM, Nguyen N, Lee NR, Hong J, Kim BW, Lee H, Lee CS, Jeong BC, et al. MG53-induced IRS-1 ubiquitination negatively regulates skeletal myogenesis and insulin signalling.Nat Commun. 2013; 4:2354. doi: 10.1038/ncomms3354CrossrefMedlineGoogle Scholar4. Cai C, Masumiya H, Weisleder N, Matsuda N, Nishi M, Hwang M, Ko JK, Lin P, Thornton A, Zhao X, et al. MG53 nucleates assembly of cell membrane repair machinery.Nat Cell Biol. 2009; 11:56–64. doi: 10.1038/ncb1812CrossrefMedlineGoogle Scholar5. Zhang C, Chen B, Wang Y, Guo A, Tang Y, Khataei T, Shi Y, Kutschke WJ, Zimmerman K, Weiss RM, et al. MG53 is dispensable for T-tubule maturation but critical for maintaining T-tubule integrity following cardiac stress.J Mol Cell Cardiol. 2017; 112:123–130. doi: 10.1016/j.yjmcc.2017.08.007CrossrefMedlineGoogle Scholar6. Liu J, Zhu H, Zheng Y, Xu Z, Li L, Tan T, Park KH, Hou J, Zhang C, Li D, et al. Cardioprotection of recombinant human MG53 protein in a porcine model of ischemia and reperfusion injury.J Mol Cell Cardiol. 2015; 80:10–19. doi: 10.1016/j.yjmcc.2014.12.010CrossrefMedlineGoogle Scholar7. Wu HK, Zhang Y, Cao CM, Hu X, Fang M, Yao Y, Jin L, Chen G, Jiang P, Zhang S, et al. Glucose-sensitive myokine/cardiokine mg53 regulates systemic insulin response and metabolic homeostasis.Circulation. 2019; 139:901–914. doi: 10.1161/CIRCULATIONAHA.118.037216LinkGoogle Scholar8. Duann P, Li H, Lin P, Tan T, Wang Z, Chen K, Zhou X, Gumpper K, Zhu H, Ludwig T, et al. MG53-mediated cell membrane repair protects against acute kidney injury.Sci Transl Med. 2015; 7:279ra–27236. doi: 10.1126/scitranslmed.3010755CrossrefGoogle Scholar9. Weisleder N, Takizawa N, Lin P, Wang X, Cao C, Zhang Y, Tan T, Ferrante C, Zhu H, Chen PJ, et al. Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy.Sci Transl Med. 2012; 4:139ra–13185. doi: 10.1126/scitranslmed.3003921CrossrefGoogle Scholar10. Bian Z, Wang Q, Zhou X, Tan T, Park KH, Kramer HF, McDougal A, Laping NJ, Kumar S, Adesanya TMA, et al. Sustained elevation of MG53 in the bloodstream increases tissue regenerative capacity without compromising metabolic function.Nat Commun. 2019; 10:4659. doi: 10.1038/s41467-019-12483-0CrossrefMedlineGoogle Scholar11. Yao Y, Zhang B, Zhu H, Li H, Han Y, Chen K, Wang Z, Zeng J, Liu Y, Wang X, et al. MG53 permeates through blood-brain barrier to protect ischemic brain injury.Oncotarget. 2016; 7:22474–22485. doi: 10.18632/oncotarget.7965CrossrefMedlineGoogle Scholar12. Wang Q, Bian Z, Jiang Q, Wang X, Zhou X, Park KH, Hsueh W, Whitson BA, Haggard E, Li H, et al. MG53 does not manifest the development of diabetes in db/db mice.Diabetes. 2020; 69:1052–1064. doi: 10.2337/db19-0807CrossrefMedlineGoogle Scholar13. Feng H, Shen H, Robeson MJ, Wu YH, Wu HK, Chen GJ, Zhang S, Xie P, Jin L, He Y, et al. MG53 E3 ligase-dead mutant protects diabetic hearts from acute ischemic/reperfusion injury and ameliorates diet-induced cardiometabolic damage.Diabetes. 2022; 71:298–314. doi: 10.2337/db21-0322CrossrefMedlineGoogle Scholar14. Lv F, Wang Y, Shan D, Guo S, Chen GJ, Jin L, Zheng W, Feng H, Zeng X, Zhang S, et al. Breaking GSK3β-MG53S255 phosphorylation-insulin resistance vicious cycle to treat diabetes associated acute myocardial injury.Circ Res. 2022Google Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesBlocking MG53S255 Phosphorylation Protects Diabetic Heart From Ischemic InjuryFengxiang Lv, et al. Circulation Research. 2022;131:962-976 December 2, 2022Vol 131, Issue 12 Advertisement Article InformationMetrics © 2022 American Heart Association, Inc.https://doi.org/10.1161/CIRCRESAHA.122.322132PMID: 36454851 Originally publishedDecember 1, 2022 PDF download Advertisement